Lee's Pharmaceutical Holdings (FRA:L1PA) Beta: -0.2285 (As of Jun. 26, 2026)


FRA:L1PA Lee's Pharmaceutical Holdings Ltd FRA:L1PA
74 GF Score
Price €0.11
GF Value €0.18
! 5 Warning Signs
View Full Analysis

What is Lee's Pharmaceutical Holdings Beta?

Lee's Pharmaceutical Holdings FRA:L1PA -4.46% 74 Beta is -0.2285 as of Jun. 26, 2026. GuruFocus rates FRA:L1PA with a GF Score™ of 74/100 and a GF Value™ of €0.18. The stock has 5 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), Lee's Pharmaceutical Holdings's Beta is -0.2285.


Lee's Pharmaceutical Holdings  (FRA:L1PA) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Lee's Pharmaceutical Holdings Beta Related Terms


Lee's Pharmaceutical Holdings Beta Historical Data

* Premium members only.

The historical data trend for Lee's Pharmaceutical Holdings's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lee's Pharmaceutical Holdings Beta Chart

Lee's Pharmaceutical Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.75 0.30 0.30 0.13 0.30

Lee's Pharmaceutical Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.30 0.15 0.13 0.15 0.30

FRA:L1PA vs ZTS: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Lee's Pharmaceutical Holdings's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lee's Pharmaceutical Holdings Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lee's Pharmaceutical Holdings's Beta distribution charts can be found below:

* The bar in red indicates where Lee's Pharmaceutical Holdings's Beta falls into.


FRA:L1PA
74GF Score
Lee's Pharmaceutical Holdings Ltd FRA:L1PA
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lee's Pharmaceutical Holdings Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -0.2285 mean?
Lee's Pharmaceutical Holdings (FRA:L1PA) has a Beta of -0.2285 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Lee's Pharmaceutical Holdings and its competitors.
Is Lee's Pharmaceutical Holdings' Beta too high?
Lee's Pharmaceutical Holdings' current Beta is -0.2285. Overall, Lee's Pharmaceutical Holdings has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Lee's Pharmaceutical Holdings' Beta compare to ZTS?
Lee's Pharmaceutical Holdings' Beta of -0.2285 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Lee's Pharmaceutical Holdings and its competitors. Lee's Pharmaceutical Holdings's current Beta is -0.2285. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lee's Pharmaceutical Holdings stock overvalued right now?
Lee's Pharmaceutical Holdings (FRA:L1PA) has a current Beta of -0.2285. The stock's GF Value™ is €0.18, compared to a current price of €0.11 — trading 40.6% below its estimated fair value. The current Beta is -0.2285. Lee's Pharmaceutical Holdings' overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Lee's Pharmaceutical Holdings (FRA:L1PA), the current Beta is -0.2285 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lee's Pharmaceutical Holdings (FRA:L1PA) Overvalued in 2026?

Based on GuruFocus' analysis, Lee's Pharmaceutical Holdings stock appears to be undervalued. The current stock price of €0.11 is trading 40.6% below its estimated GF Value™ of €0.18.

Key valuation signals for FRA:L1PA:

  • Beta: -0.2285
  • GF Value™: €0.18 vs. price of €0.11 (40.6% below fair value)
  • GF Score™: 74/100 with 5 warning signs

No single metric tells the full story. See the FRA:L1PA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lee's Pharmaceutical Holdings Business Description

Other Exchanges 00950:Hong Kong
Address Hong Kong Science Park, 1st Floor, Building 20E, Phase 3, Shatin, Hong Kong, HKG
Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue; and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.
74GF Score

Get the complete analysis for FRA:L1PA

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.11
Price
€0.18
GF Value